Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.

Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.

2.

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.

Henry RE, Barry ER, Castriotta L, Ladd B, Markovets A, Beran G, Ren Y, Zhou F, Adam A, Zinda M, Reimer C, Qing W, Su W, Clark E, D'Cruz CM, Schuller AG.

Oncotarget. 2016 Sep 6;7(36):57651-57670. doi: 10.18632/oncotarget.10859.

3.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, Norman RA, Pearson SE, Tonge M, Davies G, Walker GE, Wilson Z, Rowlinson R, Powell S, Sadler C, Richmond G, Ladd B, Pazolli E, Mazzola AM, D'Cruz C, De Savi C.

Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.

PMID:
27020862
4.

Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.

Bradford JR, Wappett M, Beran G, Logie A, Delpuech O, Brown H, Boros J, Camp NJ, McEwen R, Mazzola AM, D'Cruz C, Barry ST.

Oncotarget. 2016 Apr 12;7(15):20773-87. doi: 10.18632/oncotarget.8014.

5.

The Legend of the Pediatric Pathology Club and its Infamous Knights (with Apologies to Monty Python and the Holy Grail).

D'Cruz C.

Pediatr Dev Pathol. 2015 Nov-Dec;18(6):522-3. doi: 10.2350/15-10-1718-OA.1. Epub 2015 Dec 23. No abstract available.

PMID:
26699242
6.

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.

Mol Cancer Ther. 2015 Nov;14(11):2508-18. doi: 10.1158/1535-7163.MCT-15-0365. Epub 2015 Sep 10.

7.

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.

Davies BR, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K, Jenkins EL.

Mol Cancer Ther. 2015 Nov;14(11):2441-51. doi: 10.1158/1535-7163.MCT-15-0230. Epub 2015 Sep 8.

8.

Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.

Yates JW, Dudley P, Cheng J, D'Cruz C, Davies BR.

Cancer Chemother Pharmacol. 2015 Aug;76(2):343-56. doi: 10.1007/s00280-015-2795-7. Epub 2015 Jun 20.

PMID:
26092323
9.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.

Schuller AG, Barry ER, Jones RD, Henry RE, Frigault MM, Beran G, Linsenmayer D, Hattersley M, Smith A, Wilson J, Cairo S, Déas O, Nicolle D, Adam A, Zinda M, Reimer C, Fawell SE, Clark EA, D'Cruz CM.

Clin Cancer Res. 2015 Jun 15;21(12):2811-9. doi: 10.1158/1078-0432.CCR-14-2685. Epub 2015 Mar 16.

10.

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.

Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2015 Feb 10;6(4):2407-20.

11.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

12.

Learning curve for endobronchial ultrasound‑guided transbronchial needle aspiration: experience of a community‑based teaching hospital.

Wang H, D'Cruz C, Yam DC, Dilla LM, Tsang P.

Mol Med Rep. 2014 Nov;10(5):2441-6. doi: 10.3892/mmr.2014.2533. Epub 2014 Sep 3.

PMID:
25189939
13.

Follow-up of breast papillary lesion on core needle biopsy: experience in African-American population.

Wang H, Tsang P, D'Cruz C, Clarke K.

Diagn Pathol. 2014 Apr 24;9:86. doi: 10.1186/1746-1596-9-86.

14.

Nigerian bonny-light crude oil induces alteration in testicular stress response proteins and caspase-3 dependent apoptosis in albino wistar rats.

Ebokaiwe AP, D'Cruz CS, Jubendradass R, Amala Rani JS, Mathur PP, Farombi EO.

Environ Toxicol. 2015 Feb;30(2):242-52. doi: 10.1002/tox.21902. Epub 2013 Sep 17.

PMID:
24106129
15.

Thyroid papillary carcinoma in a 3-year-old American boy with a family history of thyroid cancer: a case report and literature review.

Khara L, Silverman A, Bethel C, D'Cruz C, Sun X.

J Pediatr Hematol Oncol. 2010 Apr;32(3):e118-21. doi: 10.1097/MPH.0b013e3181c97c57. Review.

PMID:
20216232
16.

Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo.

Liu Z, Wang M, Alvarez JV, Bonney ME, Chen CC, D'Cruz C, Pan TC, Tadesse MG, Chodosh LA.

Genome Biol. 2008;9(12):R180. doi: 10.1186/gb-2008-9-12-r180. Epub 2008 Dec 18.

17.

Finite de Finetti theorem for infinite-dimensional systems.

D'Cruz C, Osborne TJ, Schack R.

Phys Rev Lett. 2007 Apr 20;98(16):160406. Epub 2007 Apr 19.

PMID:
17501401
18.

c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1.

Cowling VH, D'Cruz CM, Chodosh LA, Cole MD.

Mol Cell Biol. 2007 Jul;27(14):5135-46. Epub 2007 May 7.

19.

Homozygous transthyretin mutation in an African American Male.

Jacob EK, Edwards WD, Zucker M, D'Cruz C, Seshan SV, Crow FW, Highsmith WE.

J Mol Diagn. 2007 Feb;9(1):127-31.

20.

Lymphoepithelioma-like carcinoma of the vulva.

Niu W, Heller DS, D'Cruz C.

J Low Genit Tract Dis. 2003 Jul;7(3):184-6.

PMID:
17051066

Supplemental Content

Loading ...
Support Center